Amcor (AMCR) Q4 2026 Earnings Call Transcript
Amcor (AMCR) reported Q4 2026 adjusted EPS of $1.23 (+23% y/y) and net sales of $6.4B (+26% reported), citing the Berry Global acquisition and higher raw material pass-through. FY revenue rose to $23.5B (+57%). Management reaffirmed a $650M three-year synergy target and guided adjusted EPS of $1.80 to $1.90 for the next six months.
How this was made
The 30-second read
Why it matters
Key trading inputs are the Q4 adjusted EPS and net sales growth, reaffirmed three-year synergy target ($650 million by end of calendar 2027), transition-period adjusted EPS guidance ($1.80 to $1.90), and explicit working-capital drag tied to the Middle East conflict.
Market read
This is a primary earnings-call disclosure with quantified guidance and synergy/cash-flow drivers, which can drive near-term repricing and positioning in AMCR.
What to watch
Leverage is only targeted to fall to ~3.0x by end of calendar 2027, so equity risk may remain elevated if cash recovery timing slips or synergy capture slows.
Background
Amcor’s fiscal 2026 Q4 call covers integration progress from the Berry Global acquisition, synergy realization, and a transition period as the company aligns its reporting cycle to Dec. 31.
Ticker impact
Amcor reported Q4 adjusted EPS of $1.23 and guided transition-period adjusted EPS to $1.80 to $1.90 for 6 months ending Dec. 31, 2026.
Likely positive bias as guidance and synergy capture (ahead of expectations) can offset working-capital drag from the Middle East conflict.
The article provides multiple concrete, decision-relevant datapoints: Q4 EPS, FY revenue growth including Berry acquisition, synergy capture vs expectations, and a specific EPS range for the next six months, all tied to integration progress and leverage reduction targets.
Market effects
Packaging peers may re-rate on read-across for integration-driven margin expansion and synergy realization credibility.
Working-capital drag tied to Middle East receivables highlights geopolitical sensitivity for global industrial packaging cash flows.
GLP-1 packaging participation and pharma mix shift can reinforce demand durability narratives for specialized packaging suppliers.
Counterpoint
The guidance and cash flow are still constrained by working-capital impacts (about $500 million) and segment volume softness in lower-margin medical categories, which could limit upside.
Key entities
- companyAmcor plc
Packaging company reporting Q4 2026 results, synergy progress from Berry acquisition, and transition-period EPS guidance.
- executivePeter Konieczny
CEO who discussed integration progress, synergy pipeline, and mix shift toward higher-margin pharma products.
- executiveStephen Scherger
CFO who quantified working-capital impacts and provided guidance bridge items including interest and taxes.
